Expression of podoplanin and vimentin is correlated with prognosis in esophageal squamous cell carcinoma

Tanaka,Makiko; Kijima,Hiroshi; Shimada,Hideo; Makuuchi,Hiroyasu; Ozawa,Soji; Inokuchi,Sadaki

doi:10.3892/mmr.2015.3966

Expression of podoplanin and vimentin is correlated with prognosis in esophageal squamous cell carcinoma

Authors:
- Makiko Tanaka
- Hiroshi Kijima
- Hideo Shimada
- Hiroyasu Makuuchi
- Soji Ozawa
- Sadaki Inokuchi
View Affiliations

Affiliations: Department of Critical Care and Emergency Medicine, Tokai University School of Medicine, Isehara, Kanagawa 259‑1193, Japan, Department of Pathology and Bioscience, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan, Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Kanagawa 259‑1193, Japan
Published online on: June 19, 2015 https://doi.org/10.3892/mmr.2015.3966
Pages: 4029-4036
Copyright: © Tanaka et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Podoplanin is a small membrane mucin, which is involved in cell migration and cancer cell invasion. However, the roles of podoplanin in esophageal squamous cell carcinoma (ESCC) are poorly understood. In the present study, 139 cases of surgically resected ESCC were analyzed and the clinicopathological significance of podoplanin membrane expression in ESCC was demonstrated. Podoplanin expression was positive in 66.2% (92/139) of ESCC samples; with weak expression in 32.4% (45/139), and strong expression in 33.8% (47/139). Membrane expression of podoplanin was significantly associated with tumor status (P=0.001), venous invasion (P=0.035) and Union for International Cancer Control stage (P=0.029). Patients who exhibited strong podoplanin expression, were shown to have a poorer prognosis [hazard ratio (HR), 3.949; 95% confidence interval (CI), 2.001‑7.794]. Expression of vimentin, a mesenchymal marker, was detected in 49 cases (35.3%) and was associated with venous invasion (P=0.020). Vimentin‑positive cases were also more likely to have a worse prognosis than vimentin‑negative cases (HR, 2.161; 95% CI, 1.300‑3.592). Podoplanin membrane expression was significantly correlated with vimentin cytoplasmic expression in ESCC (P<0.001). The present study confirmed that podoplanin and vimentin are independent predictors of mortality (HR, 3.084; 95% CI, 1.543‑6.164). These results suggest that podoplanin membrane expression results in epithelial‑mesenchymal transition and promotes aggressive invasion in human ESCC.

View Figures

View References

1	Chino O, Kijima H, Shimada H, et al: Accumulation of p53 in esophageal squamous cell carcinoma. Int J Mol Med. 8:359–363. 2001.PubMed/NCBI
2	Oshiba G, Kijima H, Himeno S, et al: Stromal thrombo-spondin-1 expression is correlated with progression of esophageal squamous cell carcinomas. Anticancer Res. 19:4375–4378. 1999.
3	Makuuchi H, Shimada H, Mizutani K, et al: Clinical pathological analysis of surgically resected superficial esophageal carcinoma to determine criteria for deciding on treatment strategy. Diagn Ther Endosc. 3:211–220. 1997. View Article : Google Scholar : PubMed/NCBI
4	Shimada H, Makuuchi H, Ozawa S, et al: Technique of the double-channel ESD method performed with an EEMR tube. Esophagus. 8:67–70. 2011. View Article : Google Scholar
5	Prognostic significance of CyclinD1 and E-Cadherin in patients with esophageal squamous cell carcinoma: multiinstitutional retrospective analysis. Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases. J Am Coll Surg. 192:708–718. 2001. View Article : Google Scholar : PubMed/NCBI
6	Yoneda M, Fujiwara H, Furutani A, et al: Prognostic impact of tumor IL-6 expression after preoperative chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma. Anticancer Res. 33:2699–2705. 2013.PubMed/NCBI
7	Ito E, Ozawa S, Kijima H, et al: New invasive patterns as a prognostic factor for superficial esophageal cancer. J Gastroenterol. 47:1279–1289. 2012. View Article : Google Scholar : PubMed/NCBI
8	Kaneko MK, Kato Y, Kitano T and Osawa M: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene. 378:52–57. 2006. View Article : Google Scholar : PubMed/NCBI
9	Martin-Villar E, Megías D, Castel S, et al: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci. 119:4541–4553. 2006. View Article : Google Scholar : PubMed/NCBI
10	Wicki A, Lehembre F, Wick N, et al: Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 9:261–272. 2006. View Article : Google Scholar : PubMed/NCBI
11	Rahadiani N, Ikeda J, Makino T, et al: Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. Ann Surg Oncol. 17:1311–1323. 2010. View Article : Google Scholar : PubMed/NCBI
12	Tong L, Yuan S, Feng F and Zhang H: Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study. Dis Esophagus. 25:72–80. 2012. View Article : Google Scholar
13	Zeisberg M and Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437. 2009. View Article : Google Scholar : PubMed/NCBI
14	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
15	Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
16	Jin H, Morohashi S, Sato F, et al: Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. Biomed Res. 31:105–112. 2010. View Article : Google Scholar : PubMed/NCBI
17	Mendez MG, Kojima S and Goldman RD: Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 24:1838–1851. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sobin LH, Gospodrowicz MK and Wittekind C: TNM Classification of Malignant Tumors. 7th edition. Wiley; Hoboken, NJ, USA: 2009
19	Japanese Gastric Cancer Association: Japan classification of gastric carcinoma, 2nd English edition. Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar
20	Shimada Y, Ishii G, Nagai K, et al: Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci. 100:2054–2059. 2009. View Article : Google Scholar : PubMed/NCBI
21	Yuan P, Temam S, El-Naggar A, et al: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 107:563–569. 2006. View Article : Google Scholar : PubMed/NCBI
22	Suzuki H, Onimaru M, Yonemitsu Y, et al: Podoplanin in cancer cells is experimentally able to attenuate prolymphangiogenic and lymphogenous metastatic potentials of lung squamoid cancer cells. Mol Cancer. 9:2872010. View Article : Google Scholar : PubMed/NCBI
23	Sudo T, Iwaya T, Nishida N, et al: Expression of mesen-chymal markers vimentin and fibronectin: the clinical significance in esophageal squamous cell carcinoma. Ann Surg Oncol. 20(Suppl 3): S324–S335. 2013. View Article : Google Scholar
24	Wicki A and Christofori G: The potential role of podoplanin in tumour invasion. Br J Cancer. 96:1–5. 2007. View Article : Google Scholar
25	Myong NH: Loss of E-cadherin and acquisition of vimentin in epithelial-mesenchymal transition are noble indicators of uterine cervix cancer progression. Korean J Pathol. 46:341–348. 2012. View Article : Google Scholar : PubMed/NCBI
26	Le Bras GF, Allison GL, Richards NF, et al: CD44 upregulation in E-cadherin-negative esophageal cancers results in cell invasion. PLoS One. 6:e270632011. View Article : Google Scholar : PubMed/NCBI
27	Usami Y, Satake S, Nakayama F, et al: Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. J Pathol. 215:330–339. 2008. View Article : Google Scholar : PubMed/NCBI
28	Hendrix MJ, Seftor EA, Seftor RE and Trevor KT: Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol. 150:483–495. 1997.PubMed/NCBI
29	Dauphin M, Barbe C, Lemaire S, et al: Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer. 81:117–122. 2013. View Article : Google Scholar : PubMed/NCBI